A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium

Abstract

The carboplatin-based MVNCa regimen is active in the treatment of patients with advanced transitional cell carcinoma and is well tolerated. Therapy with this regimen may be a less toxic alternative for patients for whom treatment with cisplatin is not an option.